BackVeradermicsorporated Overview
Veradermics, Incorporated

Veradermicsorporated Target Price

Analysts' average 12-month price target for Veradermicsorporated is $160.

Get informed when a big investor buys or sells

+ Follow

Share Price

$98.97

Average Target Price

$162.6764.4% upside

3 analysts in the last 4 months

High: $182 | Low: $136

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-15UBS$17071.8% upsideOpen
2026-07-07Jefferies$18283.9% upsideOpen
2026-06-02Needham$13637.4% upsideOpen
2026-03-02JefferiesRoger Song$7524.2% downsideOpen

Veradermicsorporated (MANE) FAQ

Veradermicsorporated posts a target price of $160. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $160 for MANE means covering analysts, on average, see the stock 64.4% upside of $98.97 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for MANE's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Veradermicsorporated's other metric pages and overview cover the third.

Judging Veradermicsorporated against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $160 here, then scan peer and history charts to see if the gap is persistent.